# Tesamorelin Dosage: The Regimens Studied in the Trials

> Tesamorelin dosage in research context: 2 mg/day subcutaneous was the dose in both pivotal Phase 3 trials. Route, half-life, and stability — cited, no human dosing advice.

What dose was administered, by which route, for how long, and what the pharmacokinetics looked like — reported as study facts, not as guidance.

## The short version

Here is the **tesamorelin dosage** picture from the studies, in plain terms — and a clear boundary first: this page reports what researchers administered, never what anyone should take. In the pivotal trials, the dose was 2 mg injected under the skin once a day. The peptide leaves the blood quickly (within the hour), but the IGF-1 growth signal it switches on stays up all day, which is why once-daily dosing was enough. There are no human dosing instructions here — only the regimens the published literature documents, each cited to its source.

## The studied dose: 2 mg/day subcutaneous

The regimen used in both pivotal Phase 3 trials, and the FDA-approved dose, was 2 mg administered subcutaneously once daily [1][2]. The 26-week NEJM trial and the 52-week program both used this dose [1][2]. A lower 1 mg arm was studied in the 12-week dose-ranging trial, where it produced a smaller IGF-I rise (+48% versus +65% at 2 mg), establishing the dose-response relationship [8].

To be explicit about framing: these are doses administered to participants in clinical trials — "studied at 2 mg/day in HIV patients" — not a recommendation for any individual. The approved product is a prescription drug for a specific HIV indication; research-grade tesamorelin is supplied for laboratory research and is not approved for general human self-administration [5].

## Route of administration

Subcutaneous injection at an abdominal site is the only route studied in clinical trials and the only FDA-approved route [1][14]. There is no published oral, intranasal, or other-route efficacy data for tesamorelin — the peptide would not survive oral digestion, which is true of GHRH analogues generally. Every efficacy figure on this site derives from once-daily subcutaneous administration [1][2][3].

## Half-life and pharmacokinetics

Tesamorelin's pharmacokinetics are the reason a short-lived peptide works on a once-daily schedule. Population PK modeling reported apparent plasma clearance of approximately 1,060 L/h, with no clinically relevant demographic covariates and roughly a 13% increase in absorbed fraction by day 14 versus day 1 [16]. Secondary sources, including the FDA label, place the terminal half-life on the order of 26-38 minutes [14].

Despite that rapid clearance, the downstream IGF-1 elevation persists across the dosing interval — the biological effect outlasts the molecule, which is the pharmacologic basis for once-daily dosing [16]. This split between a short plasma half-life and a sustained downstream effect is a recurring theme in the GHRH-analogue literature.

## Formulation and stability

Stability is engineered into the molecule and the formulation. The trans-3-hexenoic acid modification on the N-terminus blocks the DPP-IV cleavage that rapidly inactivates native GHRH, extending the peptide's biological activity [6]. The clinical product is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before subcutaneous injection; the FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window [14]. These handling facts are reported here as documented product characteristics, not as preparation instructions.

## Duration in the trials

Trial durations defined what was measured. Significant visceral-fat reduction appeared at 26 weeks in the pivotal RCTs and was sustained at roughly -18% over 52 weeks of continued dosing [1][2]. The dose-ranging study ran 12 weeks [8], and the JAMA liver-fat trial ran 6 months [3]. Across the program, the effect was contingent on continued administration — visceral fat reaccumulated within weeks of stopping [2]. There is no studied "cycle" or tapering schedule in the human literature beyond continuous once-daily dosing.

---

The tesamorelin literature walked node by node — each trial figure, the GHRH-to-IGF-1 cascade, and the FDA-HIV-only scope chalked up where the studies put them and cited to source; a teaching board, not a clinic, a vendor, or a prescription.